Zogenix has bounced back from the FDA’s rejection of its only drug, with the acquisition of Modis Therapeutics and a developmental rare disease drug that has already been championed by regu
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
